Get started
Author

Cornedine Jannette de Gooijer

Observed names: C. Gooijer, C. J. de Gooijer, C. de Gooijer, C.J. De Gooijer, C.J. de Gooijer, Cornedine J de Gooijer, Cornedine J. De Gooijer, Cornedine J. Gooijer, Cornedine J. de Gooijer, Gooijer, C.J. de, de Gooijer, Cornedine J.
ORCID: 0000-0002-4447-0149
Observed ORCID: 0000-0002-4447-0149
OpenAlex ID: A5000283061
Immunotherapy in Malignant Pleural Mesothelioma
2020 · Cornedine J. de Gooijer, Frank J. Borm, et al. · Frontiers in Oncology · 82
PDF
T3‐T4 laryngeal cancer in The Netherlands Cancer Institute; 10‐year results of the consistent application of an organ‐preserving/‐sacrificing protocol
2014 · Adriana J. Timmermans, Cornedine J. de Gooijer, et al. · Head & Neck · 59
PDF
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
2021 · Cornedine J de Gooijer, Vincent van der Noort, et al. · The Lancet Respiratory Medicine · 50
Current chemotherapy strategies in malignant pleural mesothelioma
2018 · Cornedine Jannette de Gooijer, Paul Baas, et al. · Translational Lung Cancer Research · 46
PDF
Pembrolizumab for the treatment of non-small cell lung cancer
2017 · Mirte Muller, Robert D. Schouten, et al. · Expert Review of Anticancer Therapy · 46
Real life experience with nivolumab for the treatment of non-small cell lung carcinoma
2017 · Robert D. Schouten, Mirte Muller, et al. · Lung Cancer · 44
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
2020 · Luca Cantini, Robert A. Belderbos, et al. · Translational Lung Cancer Research · 37
PDF
Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma
2023 · D.W. Dumoulin, L.H. Douma, et al. · Lung Cancer · 33
PDF
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response
2021 · Floris Dammeijer, Cornedine J. De Gooijer, et al. · EBioMedicine · 28
PDF
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
2023 · M. Jebbink, A.J. de Langen, et al. · JTO Clinical and Research Reports · 24
PDF
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
2023 · Li-Anne H Douma, Ferry Lalezari, et al. · The Lancet Oncology · 23
Artificial Intelligence–based Quantification of Pleural Plaque Volume and Association With Lung Function in Asbestos-exposed Patients
2023 · Kevin B.W. Groot Lipman, Thierry N. Boellaard, et al. · Journal of Thoracic Imaging · 11
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
2022 · René J. Boosman, Cornedine J. de Gooijer, et al. · Pharmaceutical Research · 11
PDF
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care
2020 · Robert D. Schouten, Lucie Egberink, et al. · Translational Lung Cancer Research · 11
PDF
Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
2019 · S.A. Burgers, C. de Gooijer, et al. · Annals of Oncology · 10
PDF
Follow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study—FLORA
2025 · L.H. Douma, M.M. Hofman, et al. · ESMO Open · 9
MA02.07 T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial
2021 · M. Jebbink, A.J. De Langen, et al. · Journal of Thoracic Oncology · 6
PDF
Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus
2018 · Cornedine J. de Gooijer, Paul Baas · Journal of Thoracic Oncology · 6
PDF
Artificial intelligence-based diagnosis of asbestosis: analysis of a database with applicants for asbestosis state aid
2022 · Kevin B. W. Groot Lipman, Cornedine J. de Gooijer, et al. · European Radiology · 5
PDF
Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study
2025 · Li-Anne H Douma, Vincent van der Noort, et al. · The Lancet Oncology · 4
Prospective validation of an artificial intelligence assessment in a cohort of applicants seeking financial compensation for asbestosis (PROSBEST)
2025 · Illaa Smesseim, Kevin B. W. Groot Lipman, et al. · European Radiology Experimental · 4
PDF
Impact of centralization of care for malignant peritoneal mesothelioma: A historical cohort study from the Dutch mesothelioma expert centers
2022 · Job P. van Kooten, Cornedine J. de Gooijer, et al. · European Journal of Surgical Oncology · 4
PDF
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study
2026 · Kevin B W Groot Lipman, Rianne Wittenberg, et al. · The Lancet Oncology · 2
OA18.04 Pembrolizumab Plus Lenvatinib in Second-Line Pleural Mesothelioma Patients: A Single Arm Phase II Study (PEMMELA Cohort 2)
2024 · L.H. Douma, V.v.d. Noort, et al. · Journal of Thoracic Oncology · 2
PDF
OA04.06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)
2022 · L.-A.H. Douma, C.J. de Gooijer, et al. · Journal of Thoracic Oncology · 2
Works count: 40
Citation count: 567
H-index: 11
I10-index: 15
Year
Topic
Type